http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 17 Aug 2026 06:43:46 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Kodiak+Sciences+Inc.+%28KOD%29/26934546.html <p>H.C. Wainwright analyst Matthew Caufield reiterated a Buy rating and $58.00 price target on Kodiak Sciences Inc. (NASDAQ: KOD).</p><p>The analyst commented: "The greatest near-term catalysts for the retinal therapeutics pipeline are: (1) the Phase 3 DAYBREAK trial one-year primary endpoint topline in treatment-naïve wet AMD patients anticipated in September 2026, for both the reformulated Zenkuda (tarcocimab tedromer, anti-VEGF) and KSI-501 (anti-VEGF, anti-IL-6); and (2) the Phase 3 PEAK pivotal analysis-1 topline in Macular Edema Secondary to Inflammation (MESI) expected in December 2026, for bispecific trap-antibody KSI-101 (anti-VEGF, anti-IL-6), the unconjugated protein portion of KSI-501. Most importantly, the upcoming DAYBREAK topline http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Kodiak+Sciences+Inc.+%28KOD%29/26934546.html Mon, 17 Aug 2026 06:43:46 -0400 KOD http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Kodiak+Sciences+Inc.+++++++++++++++++++Filed+by%3A+PRICE+T+ROWE+ASSOCIATES+INC+MD/26926594.html si-local-file:///var/storage/secattach/20260814/26926594.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Kodiak+Sciences+Inc.+++++++++++++++++++Filed+by%3A+PRICE+T+ROWE+ASSOCIATES+INC+MD/26926594.html Fri, 14 Aug 2026 10:39:00 -0400 KOD O.56010001 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Kodiak+Sciences+Inc.+++++++++++++++++++Filed+by%3A+PRICE+T+ROWE+ASSOCIATES+INC+MD/26926594.html si-local-file:///var/storage/secattach/20260814/26926594.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Kodiak+Sciences+Inc.+++++++++++++++++++Filed+by%3A+PRICE+T+ROWE+ASSOCIATES+INC+MD/26926594.html Fri, 14 Aug 2026 10:39:00 -0400 KOD O.56010001 http://www.streetinsider.com/Earnings/Kodiak+Sciences+Inc.+%28KOD%29+Misses+Q2+EPS+by+7c/26922086.html <p>Kodiak Sciences Inc. (NASDAQ: KOD) reported Q2 EPS of ($1.05), $0.07 worse than the analyst estimate of ($0.98).</p><p>For earnings history and earnings-related data on Kodiak Sciences Inc. (KOD) <a href="http://www.streetinsider.com/ec_earnings.php?q=KOD">click here</a>.</p> http://www.streetinsider.com/Earnings/Kodiak+Sciences+Inc.+%28KOD%29+Misses+Q2+EPS+by+7c/26922086.html Thu, 13 Aug 2026 16:39:14 -0400 KOD http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Kodiak+Sciences+Inc.++++++For%3A+Jun+30/26921462.html si-local-file:///var/storage/secattach/20260813/26921462.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Kodiak+Sciences+Inc.++++++For%3A+Jun+30/26921462.html Thu, 13 Aug 2026 16:18:00 -0400 KOD O.56010001 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Kodiak+Sciences+Inc.++++++For%3A+Jun+30/26921462.html si-local-file:///var/storage/secattach/20260813/26921462.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Kodiak+Sciences+Inc.++++++For%3A+Jun+30/26921462.html Thu, 13 Aug 2026 16:18:00 -0400 KOD O.56010001 http://www.streetinsider.com/Press+Releases/Kodiak+Sciences+Announces+Recent+Business+Highlights+and+Second+Quarter+2026+Financial+Results/26920467.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.paloal" idsrc="xmltag.org" >PALO ALTO, Calif.</location></span>, <span class="legendSpanClass"><chron>Aug. 13, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:KOD" idsrc="xmltag.org" >Kodiak Sciences Inc.</span> (Nasdaq: KOD), today reported recent business highlights and financial results for the second quarter ended <chron>June 30, 2026</chron>.</p> <p>"Kodiak continues to execute broadly across our late-stage clinical portfolio as we approach three Phase 3 readouts between now and the end of this year," said <person>Victor Perlroth</person>, M.D., Chief Executive Officer of <span value="NASDAQ-NMS:KOD" idsrc="xmltag.org" >Kodiak Sciences</span>.</p><p>"We remain on track for <chron>September 2026</chron> DAYBREAK Phase 3 topline results evaluating both Zenkuda and KSI-501 in treatment-naïve wet AMD, followed by <chron>December 2026</chron> PEAK Phase http://www.streetinsider.com/Press+Releases/Kodiak+Sciences+Announces+Recent+Business+Highlights+and+Second+Quarter+2026+Financial+Results/26920467.html Thu, 13 Aug 2026 16:00:00 -0400 A.04656558 KOD O.17919713 O.56010001 http://www.streetinsider.com/Press+Releases/Kodiak+Sciences+Announces+Recent+Business+Highlights+and+Second+Quarter+2026+Financial+Results/26920467.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.paloal" idsrc="xmltag.org" >PALO ALTO, Calif.</location></span>, <span class="legendSpanClass"><chron>Aug. 13, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:KOD" idsrc="xmltag.org" >Kodiak Sciences Inc.</span> (Nasdaq: KOD), today reported recent business highlights and financial results for the second quarter ended <chron>June 30, 2026</chron>.</p> <p>"Kodiak continues to execute broadly across our late-stage clinical portfolio as we approach three Phase 3 readouts between now and the end of this year," said <person>Victor Perlroth</person>, M.D., Chief Executive Officer of <span value="NASDAQ-NMS:KOD" idsrc="xmltag.org" >Kodiak Sciences</span>.</p><p>"We remain on track for <chron>September 2026</chron> DAYBREAK Phase 3 topline results evaluating both Zenkuda and KSI-501 in treatment-naïve wet AMD, followed by <chron>December 2026</chron> PEAK Phase http://www.streetinsider.com/Press+Releases/Kodiak+Sciences+Announces+Recent+Business+Highlights+and+Second+Quarter+2026+Financial+Results/26920467.html Thu, 13 Aug 2026 16:00:00 -0400 A.04656558 KOD O.17919713 O.56010001 http://www.streetinsider.com/Press+Releases/Kodiak+Sciences+Announces+Recent+Business+Highlights+and+Second+Quarter+2026+Financial+Results/26920467.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.paloal" idsrc="xmltag.org" >PALO ALTO, Calif.</location></span>, <span class="legendSpanClass"><chron>Aug. 13, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:KOD" idsrc="xmltag.org" >Kodiak Sciences Inc.</span> (Nasdaq: KOD), today reported recent business highlights and financial results for the second quarter ended <chron>June 30, 2026</chron>.</p> <p>"Kodiak continues to execute broadly across our late-stage clinical portfolio as we approach three Phase 3 readouts between now and the end of this year," said <person>Victor Perlroth</person>, M.D., Chief Executive Officer of <span value="NASDAQ-NMS:KOD" idsrc="xmltag.org" >Kodiak Sciences</span>.</p><p>"We remain on track for <chron>September 2026</chron> DAYBREAK Phase 3 topline results evaluating both Zenkuda and KSI-501 in treatment-naïve wet AMD, followed by <chron>December 2026</chron> PEAK Phase http://www.streetinsider.com/Press+Releases/Kodiak+Sciences+Announces+Recent+Business+Highlights+and+Second+Quarter+2026+Financial+Results/26920467.html Thu, 13 Aug 2026 16:00:00 -0400 A.04656558 KOD O.17919713 O.56010001 http://www.streetinsider.com/Press+Releases/Kodiak+Sciences+Announces+Recent+Business+Highlights+and+Second+Quarter+2026+Financial+Results/26920467.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.paloal" idsrc="xmltag.org" >PALO ALTO, Calif.</location></span>, <span class="legendSpanClass"><chron>Aug. 13, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:KOD" idsrc="xmltag.org" >Kodiak Sciences Inc.</span> (Nasdaq: KOD), today reported recent business highlights and financial results for the second quarter ended <chron>June 30, 2026</chron>.</p> <p>"Kodiak continues to execute broadly across our late-stage clinical portfolio as we approach three Phase 3 readouts between now and the end of this year," said <person>Victor Perlroth</person>, M.D., Chief Executive Officer of <span value="NASDAQ-NMS:KOD" idsrc="xmltag.org" >Kodiak Sciences</span>.</p><p>"We remain on track for <chron>September 2026</chron> DAYBREAK Phase 3 topline results evaluating both Zenkuda and KSI-501 in treatment-naïve wet AMD, followed by <chron>December 2026</chron> PEAK Phase http://www.streetinsider.com/Press+Releases/Kodiak+Sciences+Announces+Recent+Business+Highlights+and+Second+Quarter+2026+Financial+Results/26920467.html Thu, 13 Aug 2026 16:00:00 -0400 A.04656558 KOD O.17919713 O.56010001 http://www.streetinsider.com/PRNewswire/Kodiak+Sciences+Announces+Recent+Business+Highlights+and+Second+Quarter+2026+Financial+Results/26920467.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.paloal" idsrc="xmltag.org" >PALO ALTO, Calif.</location></span>, <span class="legendSpanClass"><chron>Aug. 13, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:KOD" idsrc="xmltag.org" >Kodiak Sciences Inc.</span> (Nasdaq: KOD), today reported recent business highlights and financial results for the second quarter ended <chron>June 30, 2026</chron>.</p> <p>"Kodiak continues to execute broadly across our late-stage clinical portfolio as we approach three Phase 3 readouts between now and the end of this year," said <person>Victor Perlroth</person>, M.D., Chief Executive Officer of <span value="NASDAQ-NMS:KOD" idsrc="xmltag.org" >Kodiak Sciences</span>.</p><p>"We remain on track for <chron>September 2026</chron> DAYBREAK Phase 3 topline results evaluating both Zenkuda and KSI-501 in treatment-naïve wet AMD, followed by <chron>December 2026</chron> PEAK Phase http://www.streetinsider.com/PRNewswire/Kodiak+Sciences+Announces+Recent+Business+Highlights+and+Second+Quarter+2026+Financial+Results/26920467.html Thu, 13 Aug 2026 16:00:00 -0400 A.04656558 KOD O.17919713 O.56010001 http://www.streetinsider.com/PRNewswire/Kodiak+Sciences+Announces+Recent+Business+Highlights+and+Second+Quarter+2026+Financial+Results/26920467.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.paloal" idsrc="xmltag.org" >PALO ALTO, Calif.</location></span>, <span class="legendSpanClass"><chron>Aug. 13, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:KOD" idsrc="xmltag.org" >Kodiak Sciences Inc.</span> (Nasdaq: KOD), today reported recent business highlights and financial results for the second quarter ended <chron>June 30, 2026</chron>.</p> <p>"Kodiak continues to execute broadly across our late-stage clinical portfolio as we approach three Phase 3 readouts between now and the end of this year," said <person>Victor Perlroth</person>, M.D., Chief Executive Officer of <span value="NASDAQ-NMS:KOD" idsrc="xmltag.org" >Kodiak Sciences</span>.</p><p>"We remain on track for <chron>September 2026</chron> DAYBREAK Phase 3 topline results evaluating both Zenkuda and KSI-501 in treatment-naïve wet AMD, followed by <chron>December 2026</chron> PEAK Phase http://www.streetinsider.com/PRNewswire/Kodiak+Sciences+Announces+Recent+Business+Highlights+and+Second+Quarter+2026+Financial+Results/26920467.html Thu, 13 Aug 2026 16:00:00 -0400 A.04656558 KOD O.17919713 O.56010001 http://www.streetinsider.com/PRNewswire/Kodiak+Sciences+Announces+Recent+Business+Highlights+and+Second+Quarter+2026+Financial+Results/26920467.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.paloal" idsrc="xmltag.org" >PALO ALTO, Calif.</location></span>, <span class="legendSpanClass"><chron>Aug. 13, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:KOD" idsrc="xmltag.org" >Kodiak Sciences Inc.</span> (Nasdaq: KOD), today reported recent business highlights and financial results for the second quarter ended <chron>June 30, 2026</chron>.</p> <p>"Kodiak continues to execute broadly across our late-stage clinical portfolio as we approach three Phase 3 readouts between now and the end of this year," said <person>Victor Perlroth</person>, M.D., Chief Executive Officer of <span value="NASDAQ-NMS:KOD" idsrc="xmltag.org" >Kodiak Sciences</span>.</p><p>"We remain on track for <chron>September 2026</chron> DAYBREAK Phase 3 topline results evaluating both Zenkuda and KSI-501 in treatment-naïve wet AMD, followed by <chron>December 2026</chron> PEAK Phase http://www.streetinsider.com/PRNewswire/Kodiak+Sciences+Announces+Recent+Business+Highlights+and+Second+Quarter+2026+Financial+Results/26920467.html Thu, 13 Aug 2026 16:00:00 -0400 A.04656558 KOD O.17919713 O.56010001 http://www.streetinsider.com/PRNewswire/Kodiak+Sciences+Announces+Recent+Business+Highlights+and+Second+Quarter+2026+Financial+Results/26920467.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.paloal" idsrc="xmltag.org" >PALO ALTO, Calif.</location></span>, <span class="legendSpanClass"><chron>Aug. 13, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:KOD" idsrc="xmltag.org" >Kodiak Sciences Inc.</span> (Nasdaq: KOD), today reported recent business highlights and financial results for the second quarter ended <chron>June 30, 2026</chron>.</p> <p>"Kodiak continues to execute broadly across our late-stage clinical portfolio as we approach three Phase 3 readouts between now and the end of this year," said <person>Victor Perlroth</person>, M.D., Chief Executive Officer of <span value="NASDAQ-NMS:KOD" idsrc="xmltag.org" >Kodiak Sciences</span>.</p><p>"We remain on track for <chron>September 2026</chron> DAYBREAK Phase 3 topline results evaluating both Zenkuda and KSI-501 in treatment-naïve wet AMD, followed by <chron>December 2026</chron> PEAK Phase http://www.streetinsider.com/PRNewswire/Kodiak+Sciences+Announces+Recent+Business+Highlights+and+Second+Quarter+2026+Financial+Results/26920467.html Thu, 13 Aug 2026 16:00:00 -0400 A.04656558 KOD O.17919713 O.56010001 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Kodiak+Sciences+Inc.++++++For%3A+Aug+13/26920487.html si-local-file:///var/storage/secattach/20260813/26920487.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Kodiak+Sciences+Inc.++++++For%3A+Aug+13/26920487.html Thu, 13 Aug 2026 16:00:00 -0400 KOD O.56010001 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Kodiak+Sciences+Inc.++++++For%3A+Aug+13/26920487.html si-local-file:///var/storage/secattach/20260813/26920487.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Kodiak+Sciences+Inc.++++++For%3A+Aug+13/26920487.html Thu, 13 Aug 2026 16:00:00 -0400 KOD O.56010001 http://www.streetinsider.com/FDA/Kodiak+Sciences+enrolls+first+patients+in+Phase+3+DME+trial/26898745.html <p>Kodiak Sciences Inc. (Nasdaq: KOD) announced that the first patients have been enrolled in its global Phase 3 ALTO trial, evaluating investigational drug KSI-501 in patients with diabetic macular edema (DME).</p> <p>The ALTO trial is designed to test whether KSI-501 is superior to aflibercept, an existing anti-VEGF therapy, in treating DME. KSI-501 is a bispecific therapy that targets two pathways: interleukin-6 (IL-6)-mediated inflammation and vascular endothelial growth factor (VEGF)-mediated vascular permeability and neovascularization.</p> <p>The study will enroll approximately 910 patients, randomized across three arms. Two arms will receive KSI-501 5 mg under different dosing regimens following six monthly loading doses, while the http://www.streetinsider.com/FDA/Kodiak+Sciences+enrolls+first+patients+in+Phase+3+DME+trial/26898745.html Mon, 10 Aug 2026 16:44:08 -0400 KOD O.56010001 http://www.streetinsider.com/FDA/Kodiak+Sciences+enrolls+first+patients+in+Phase+3+DME+trial/26898745.html <p>Kodiak Sciences Inc. (Nasdaq: KOD) announced that the first patients have been enrolled in its global Phase 3 ALTO trial, evaluating investigational drug KSI-501 in patients with diabetic macular edema (DME).</p> <p>The ALTO trial is designed to test whether KSI-501 is superior to aflibercept, an existing anti-VEGF therapy, in treating DME. KSI-501 is a bispecific therapy that targets two pathways: interleukin-6 (IL-6)-mediated inflammation and vascular endothelial growth factor (VEGF)-mediated vascular permeability and neovascularization.</p> <p>The study will enroll approximately 910 patients, randomized across three arms. Two arms will receive KSI-501 5 mg under different dosing regimens following six monthly loading doses, while the http://www.streetinsider.com/FDA/Kodiak+Sciences+enrolls+first+patients+in+Phase+3+DME+trial/26898745.html Mon, 10 Aug 2026 16:44:08 -0400 KOD O.56010001 http://www.streetinsider.com/Press+Releases/Kodiak+Sciences+Announces+First+Patients+Enrolled+in+Global+Phase+3+ALTO+trial+of+KSI-501+in+Patients+with+Diabetic+Macular+Edema/26898743.html <div class="xn-content"> <ul type="disc"><li><i>Phase 3 ALTO trial designed to demonstrate superiority of KSI-501 versus aflibercept in patients with diabetic macular edema</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.paloal" idsrc="xmltag.org" >PALO ALTO, Calif.</location></span>, <span class="legendSpanClass"><chron>Aug. 10, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:KOD" idsrc="xmltag.org" >Kodiak Sciences Inc.</span> (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced that the first patients have been enrolled in the global Phase 3 ALTO trial evaluating KSI-501 in patients with diabetic macular edema (DME). KSI-501 is an investigational, first-in-class bispecific therapy built on Kodiak's <span>ABC</span>^® Platform and designed to potently inhibit two complementary pathways implicated in retinal http://www.streetinsider.com/Press+Releases/Kodiak+Sciences+Announces+First+Patients+Enrolled+in+Global+Phase+3+ALTO+trial+of+KSI-501+in+Patients+with+Diabetic+Macular+Edema/26898743.html Mon, 10 Aug 2026 16:43:00 -0400 KOD O.56010001 http://www.streetinsider.com/Press+Releases/Kodiak+Sciences+Announces+First+Patients+Enrolled+in+Global+Phase+3+ALTO+trial+of+KSI-501+in+Patients+with+Diabetic+Macular+Edema/26898743.html <div class="xn-content"> <ul type="disc"><li><i>Phase 3 ALTO trial designed to demonstrate superiority of KSI-501 versus aflibercept in patients with diabetic macular edema</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.paloal" idsrc="xmltag.org" >PALO ALTO, Calif.</location></span>, <span class="legendSpanClass"><chron>Aug. 10, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:KOD" idsrc="xmltag.org" >Kodiak Sciences Inc.</span> (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced that the first patients have been enrolled in the global Phase 3 ALTO trial evaluating KSI-501 in patients with diabetic macular edema (DME). KSI-501 is an investigational, first-in-class bispecific therapy built on Kodiak's <span>ABC</span>^® Platform and designed to potently inhibit two complementary pathways implicated in retinal http://www.streetinsider.com/Press+Releases/Kodiak+Sciences+Announces+First+Patients+Enrolled+in+Global+Phase+3+ALTO+trial+of+KSI-501+in+Patients+with+Diabetic+Macular+Edema/26898743.html Mon, 10 Aug 2026 16:43:00 -0400 KOD O.56010001 http://www.streetinsider.com/PRNewswire/Kodiak+Sciences+Announces+First+Patients+Enrolled+in+Global+Phase+3+ALTO+trial+of+KSI-501+in+Patients+with+Diabetic+Macular+Edema/26898743.html <div class="xn-content"> <ul type="disc"><li><i>Phase 3 ALTO trial designed to demonstrate superiority of KSI-501 versus aflibercept in patients with diabetic macular edema</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.paloal" idsrc="xmltag.org" >PALO ALTO, Calif.</location></span>, <span class="legendSpanClass"><chron>Aug. 10, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:KOD" idsrc="xmltag.org" >Kodiak Sciences Inc.</span> (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced that the first patients have been enrolled in the global Phase 3 ALTO trial evaluating KSI-501 in patients with diabetic macular edema (DME). KSI-501 is an investigational, first-in-class bispecific therapy built on Kodiak's <span>ABC</span>^® Platform and designed to potently inhibit two complementary pathways implicated in retinal http://www.streetinsider.com/PRNewswire/Kodiak+Sciences+Announces+First+Patients+Enrolled+in+Global+Phase+3+ALTO+trial+of+KSI-501+in+Patients+with+Diabetic+Macular+Edema/26898743.html Mon, 10 Aug 2026 16:43:00 -0400 KOD O.56010001 http://www.streetinsider.com/PRNewswire/Kodiak+Sciences+Announces+First+Patients+Enrolled+in+Global+Phase+3+ALTO+trial+of+KSI-501+in+Patients+with+Diabetic+Macular+Edema/26898743.html <div class="xn-content"> <ul type="disc"><li><i>Phase 3 ALTO trial designed to demonstrate superiority of KSI-501 versus aflibercept in patients with diabetic macular edema</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.paloal" idsrc="xmltag.org" >PALO ALTO, Calif.</location></span>, <span class="legendSpanClass"><chron>Aug. 10, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:KOD" idsrc="xmltag.org" >Kodiak Sciences Inc.</span> (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced that the first patients have been enrolled in the global Phase 3 ALTO trial evaluating KSI-501 in patients with diabetic macular edema (DME). KSI-501 is an investigational, first-in-class bispecific therapy built on Kodiak's <span>ABC</span>^® Platform and designed to potently inhibit two complementary pathways implicated in retinal http://www.streetinsider.com/PRNewswire/Kodiak+Sciences+Announces+First+Patients+Enrolled+in+Global+Phase+3+ALTO+trial+of+KSI-501+in+Patients+with+Diabetic+Macular+Edema/26898743.html Mon, 10 Aug 2026 16:43:00 -0400 KOD O.56010001 http://www.streetinsider.com/FDA/Kodiak+Sciences+completes+enrollment+in+Phase+3+PEAK+trial+cohort/26878323.html <p>Kodiak Sciences Inc. (Nasdaq: KOD) announced it has completed enrollment of the first 300-patient cohort in its Phase 3 PEAK trial evaluating KSI-101 for macular edema secondary to inflammation, known as MESI.</p> <p>The company said enrollment in the first pivotal cohort was completed in early June, and topline clinical data from the 24-week primary endpoint are expected in December 2026. This data release will constitute Pivotal Analysis 1 of the KSI-101 Phase 3 program.</p> <p>A second pivotal cohort, Pivotal Analysis 2, will evaluate 600 subjects across both the PEAK and PINNACLE studies. Enrollment in that cohort is expected to be completed in http://www.streetinsider.com/FDA/Kodiak+Sciences+completes+enrollment+in+Phase+3+PEAK+trial+cohort/26878323.html Thu, 06 Aug 2026 07:00:48 -0400 A.04656558 KOD O.17919713 O.56010001 http://www.streetinsider.com/FDA/Kodiak+Sciences+completes+enrollment+in+Phase+3+PEAK+trial+cohort/26878323.html <p>Kodiak Sciences Inc. (Nasdaq: KOD) announced it has completed enrollment of the first 300-patient cohort in its Phase 3 PEAK trial evaluating KSI-101 for macular edema secondary to inflammation, known as MESI.</p> <p>The company said enrollment in the first pivotal cohort was completed in early June, and topline clinical data from the 24-week primary endpoint are expected in December 2026. This data release will constitute Pivotal Analysis 1 of the KSI-101 Phase 3 program.</p> <p>A second pivotal cohort, Pivotal Analysis 2, will evaluate 600 subjects across both the PEAK and PINNACLE studies. Enrollment in that cohort is expected to be completed in http://www.streetinsider.com/FDA/Kodiak+Sciences+completes+enrollment+in+Phase+3+PEAK+trial+cohort/26878323.html Thu, 06 Aug 2026 07:00:48 -0400 A.04656558 KOD O.17919713 O.56010001 http://www.streetinsider.com/FDA/Kodiak+Sciences+completes+enrollment+in+Phase+3+PEAK+trial+cohort/26878323.html <p>Kodiak Sciences Inc. (Nasdaq: KOD) announced it has completed enrollment of the first 300-patient cohort in its Phase 3 PEAK trial evaluating KSI-101 for macular edema secondary to inflammation, known as MESI.</p> <p>The company said enrollment in the first pivotal cohort was completed in early June, and topline clinical data from the 24-week primary endpoint are expected in December 2026. This data release will constitute Pivotal Analysis 1 of the KSI-101 Phase 3 program.</p> <p>A second pivotal cohort, Pivotal Analysis 2, will evaluate 600 subjects across both the PEAK and PINNACLE studies. Enrollment in that cohort is expected to be completed in http://www.streetinsider.com/FDA/Kodiak+Sciences+completes+enrollment+in+Phase+3+PEAK+trial+cohort/26878323.html Thu, 06 Aug 2026 07:00:48 -0400 A.04656558 KOD O.17919713 O.56010001